Amgen

AMGN

Market cap $192B

In the most recent trading session, Amgen (AMGN) closed at $355.3, indicating a +1.69% shift from the previous trading day.

Amgen (AMGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Amgen's lung cancer drug tarlatamab has won approval from ​China's National Medical Products Administration, ‌its development and commercialisation partner BeOne Medicines said on Friday on WeChat.

Amgen (AMGN) closed at $355.6 in the latest trading session, marking a +1.66% move from the prior day.

Amgen Inc. and Eli Lilly and Company occupy leading positions in the immune-mediated inflammatory diseases treatment market. Moreover, AMGN hopes to grab a piece of the GLP-1s market from LLY. Each of them has advantages, as well as dark spots in the portfolio of drugs relative to the rival.

Amgen (AMGN) reached $349.81 at the closing of the latest trading day, reflecting a +2.89% change compared to its last close.

The stock market's weakness might not be over — but it's not too early to start building a list of stocks to consider buying when investors are willing to take on more risk.

Amgen Inc. is rated a solid Buy, supported by robust revenue growth, pipeline strength, and recent FDA approvals despite looming patent expiries on legacy drugs. Tepezza's successful Phase 3 subcutaneous trial enhances its competitive position in the Thyroid Eye Disease - TED - market, targeting expanded patient access and chronic use. AMGN's 2026 guidance projects $37–$38.4bn in revenue and non-GAAP EPS of $21.6–$23, with a forward P/E of ~17x and a diverse late-stage pipeline.

Here is how Amgen (AMGN) and BioAge Labs, Inc. (BIOA) have performed compared to their sector so far this year.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.